# Kerry L Burnstein

List of Publications by Year
in descending order



| 23 | 786 | 567281 15 | 713466 21 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 23 | 23 | 23 | 1459 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor. Oncogene, 2022, 41, 2824-2832. | 5.9 | 10 |
| 2 | Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans. Molecular Cancer Research, 2022, 20, 1295-1304. | 3.4 | 3 |
| 3 | Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Science Translational Medicine, 2019, 11, . | 12.4 | 36 |
| 4 | Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis. Oncogene, 2019, 38, 838-851. | 5.9 | 19 |
| 5 | Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723. | 1.9 | 105 |
| 6 | Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11298-11303. | 7.1 | 38 |
| 7 | Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer. Molecular Systems Biology, 2018, 14, e8202. | 7.2 | 33 |
| 8 | Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer. Nature Communications, 2017, 8, 1204. | 12.8 | 40 |
| 9 | Targeting AR Variantâ€“Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. Molecular Cancer Research, 2017, 15, 1469-1480. | 3.4 | 21 |
| 10 | Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. Molecular Cancer Therapeutics, 2016, 15, 1353-1363. | 4.1 | 15 |
| 11 | Essential Components of Cancer Education. Cancer Research, 2015, 75, 5202-5205. | 0.9 | 10 |
| 12 | VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research, 2014, 16, R53. | 5.0 | 28 |
| 13 | Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1084-1089. | 7.1 | 40 |
| 14 | A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. Oncotarget, 2014, 5, 9007-9021. | 1.8 | 6 |
| 15 | Preclinical efficacy of growth hormone-releasing hormone antagonist MIA-602 for androgen-dependent and castration-resistant human prostate cancer.. Journal of Clinical Oncology, 2014, 32, 221-221. | 1.6 | 0 |
| 16 | Signaling Mechanisms of Vav3, a Guanine Nucleotide Exchange Factor and Androgen Receptor Coactivator, in Physiology and Prostate Cancer Progression. , 2013, , 187-205. | | 0 |
| 17 | Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts. Molecular Cancer Therapeutics, 2013, 12, 394-404. | 4.1 | 25 |
| 18 | Novel Interaction between the Co-chaperone Cdc37 and Rho GTPase Exchange Factor Vav3 Promotes Androgen Receptor Activity and Prostate Cancer Growth*. Journal of Biological Chemistry, 2013, 288, 5463-5474. | 3.4 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The microRNA -23b/-27b Cluster Suppresses the Metastatic Phenotype of Castration-Resistant Prostate Cancer Cells. PLoS ONE, 2012, 7, e52106. | 2.5 | 78 |
| 20 | Vav3 Enhances Androgen Receptor Splice Variant Activity and Is Critical for Castration-Resistant Prostate Cancer Growth and Survival. Molecular Endocrinology, 2012, 26, 1967-1979. | 3.7 | 49 |
| 21 | Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer. Molecular Endocrinology, 2008, 22, 597-608. | 3.7 | 46 |
| 22 | Vav3, a Rho GTPase Guanine Nucleotide Exchange Factor, Increases during Progression to Androgen Independence in Prostate Cancer Cells and Potentiates Androgen Receptor Transcriptional Activity. Molecular Endocrinology, 2006, 20, 1061-1072. | 3.7 | 58 |
| 23 | Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy. Journal of Cellular Biochemistry, 2005, 95, 657-669. | 2.6 | 106 |